Core Viewpoint - Furuya Medical Technology (01696) experienced a significant decline of over 11%, with a current price of HKD 6.18 and a trading volume of HKD 18.245 million following the release of its mid-year results for 2025, indicating challenges in the North American market and a decrease in profitability [1][1][1] Financial Performance - The company reported revenues of USD 165 million for the mid-year period, reflecting a year-on-year decrease of 1.9% [1] - Net profit attributable to shareholders was USD 6.426 million, down 41.3% year-on-year [1] - Basic earnings per share were USD 0.0137 [1] Market Conditions - The decline in revenue is primarily attributed to challenging conditions in the North American market, characterized by high interest rates and weak consumer demand [1] - Transportation delays due to regional tensions in June also contributed to a slight delay in revenue recognition [1] International Market Growth - Excluding the adverse factors in the North American market, Furuya Medical Technology achieved a 7.1% growth in international markets compared to the same period in 2024 [1] Order Reserves and Profitability - As of June 30, 2025, the company's order reserves remained robust, increasing by several million dollars compared to the same period in 2024 [1] - The gross profit margin decreased from 62.4% in 2024 to 60.0% in the reporting period, primarily due to a strategic shift towards core professional and high-end products, which have higher material costs due to advanced technology specifications [1][1]
复锐医疗科技跌超11% 中期纯利同比下降41.3% 收益跌1.9%